Cue Biopharma Inc (CUE)
1.705
+0.22
(+14.81%)
USD |
NASDAQ |
Nov 05, 16:00
1.74
+0.04
(+2.05%)
After-Hours: 20:00
Cue Biopharma Revenue (Quarterly): 2.658M for June 30, 2024
Revenue (Quarterly) Chart
Historical Revenue (Quarterly) Data
Date | Value |
---|---|
June 30, 2024 | 2.658M |
March 31, 2024 | 1.717M |
December 31, 2023 | 1.821M |
September 30, 2023 | 2.10M |
June 30, 2023 | 1.382M |
March 31, 2023 | 0.187M |
December 31, 2022 | 0.151M |
September 30, 2022 | 0.068M |
June 30, 2022 | 0.026M |
March 31, 2022 | 1.00M |
December 31, 2021 | 8.254M |
September 30, 2021 | 2.395M |
June 30, 2021 | 2.739M |
Date | Value |
---|---|
March 31, 2021 | 1.553M |
December 31, 2020 | 0.4753M |
September 30, 2020 | 0.704M |
June 30, 2020 | 1.075M |
March 31, 2020 | 0.90M |
December 31, 2019 | 1.049M |
September 30, 2019 | 0.984M |
June 30, 2019 | 1.055M |
March 31, 2019 | 0.37M |
December 31, 2018 | 0.3306M |
September 30, 2018 | 0.449M |
June 30, 2018 | 0.172M |
Revenues Definition
Revenues measure the total amount of value that a company brings in during a certain period. This is also considered the "top-line" of the income statement. Revenues are used for all operating expenses as well as other line items which eventually lead to the net income for the company. Revenue is an extremely important metric when analyzing a company. A company with efficient margins is able to turn revenues into the most net income.
Revenue (Quarterly) Range, Past 5 Years
0.026M
Minimum
Jun 2022
8.254M
Maximum
Dec 2021
1.592M
Average
1.075M
Median
Jun 2020
Revenue (Quarterly) Benchmarks
Biomarin Pharmaceutical Inc | 745.74M |
Arbutus Biopharma Corp | 1.726M |
GlycoMimetics Inc | -- |
FibroGen Inc | 50.64M |
Cidara Therapeutics Inc | 0.302M |
Revenue (Quarterly) Related Metrics
Net Income (Quarterly) | -10.17M |
Total Expenses (Quarterly) | 13.04M |
EPS Diluted (Quarterly) | -0.20 |
Enterprise Value | 65.63M |
Profit Margin (Quarterly) | -382.7% |
Earnings Yield | -57.48% |
Normalized Earnings Yield | -57.28 |